Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection

Sho Miyamoto, Takeshi Arashiro, Akira Ueno, Takayuki Kanno, Shinji Saito, Harutaka Katano, Shun Iida, Akira Ainai, Seiya Ozono, Takuya Hemmi, Yuichiro Hirata, Saya Moriyama, Ryutaro Kotaki, Hitomi Kinoshita, Souichi Yamada, Masaharu Shinkai, Shuetsu Fukushi, Yoshimasa Takahashi, View ORCID ProfileTadaki Suzuki
doi: https://doi.org/10.1101/2022.06.15.22276432
Sho Miyamoto
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeshi Arashiro
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
2Center for Surveillance Immunization and Epidemiologic Research, National Institute of Infectious Diseases; 162-8640, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Ueno
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takayuki Kanno
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinji Saito
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harutaka Katano
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shun Iida
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Ainai
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiya Ozono
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takuya Hemmi
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuichiro Hirata
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saya Moriyama
3Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryutaro Kotaki
3Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hitomi Kinoshita
4Department of Virology I, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Souichi Yamada
4Department of Virology I, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaharu Shinkai
5Tokyo Shinagawa Hospital; Tokyo 140-8522, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuetsu Fukushi
4Department of Virology I, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshimasa Takahashi
3Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadaki Suzuki
4Department of Virology I, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tadaki Suzuki
  • For correspondence: tksuzuki@niid.go.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract:

Immunity to SARS-CoV-2 in COVID-19 cases has diversified due to complex combinations of exposure to vaccination and infection. Elucidating the drivers for upgrading neutralizing activity to SARS-CoV-2 in COVID-19 cases with pre-existing immunity will aid in understanding immunity to SARS-CoV-2 and improving COVID-19 booster vaccines with enhanced cross-protection against antigenically distinct variants. This study revealed that the magnitude and breadth of neutralization responses to SARS-CoV-2 infection in breakthrough infections are determined by upper respiratory viral load and vaccination-infection time interval, but not by the lineage of infecting viruses. Notably, the time interval, but not the viral load, may play a critical role in expanding the breadth of neutralization to SARS-CoV-2. This illustrates the importance of dosing interval optimization in addition to antigen design in the development of variant-proof booster vaccines.

One-Sentence Summary Viral load and infection timing define the magnitude and breadth of SARS-CoV-2 neutralization after breakthrough infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI) grant 21K20768 (SMiyamoto), and Japan Agency for Medical Research and Development (AMED) grant JP21fk0108104 (TS), JP22fk0108637 (TS), JP20fk0108534 (YT), JP21fk0108615 (YT).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Medical Research Ethics Committee of National Institute of Infectious Diseases gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵6 These authors contributed equally

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 16, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection
Sho Miyamoto, Takeshi Arashiro, Akira Ueno, Takayuki Kanno, Shinji Saito, Harutaka Katano, Shun Iida, Akira Ainai, Seiya Ozono, Takuya Hemmi, Yuichiro Hirata, Saya Moriyama, Ryutaro Kotaki, Hitomi Kinoshita, Souichi Yamada, Masaharu Shinkai, Shuetsu Fukushi, Yoshimasa Takahashi, Tadaki Suzuki
medRxiv 2022.06.15.22276432; doi: https://doi.org/10.1101/2022.06.15.22276432
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection
Sho Miyamoto, Takeshi Arashiro, Akira Ueno, Takayuki Kanno, Shinji Saito, Harutaka Katano, Shun Iida, Akira Ainai, Seiya Ozono, Takuya Hemmi, Yuichiro Hirata, Saya Moriyama, Ryutaro Kotaki, Hitomi Kinoshita, Souichi Yamada, Masaharu Shinkai, Shuetsu Fukushi, Yoshimasa Takahashi, Tadaki Suzuki
medRxiv 2022.06.15.22276432; doi: https://doi.org/10.1101/2022.06.15.22276432

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1101)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9782)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2318)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11656)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2148)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2188)
  • Public and Global Health (4673)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)